Boac Bernadette M, Xiong Yin, Marchion Douglas C, Abbasi Forough, Bush Stephen H, Ramirez Ingrid J, Khulpateea Beman R, Clair McClung E, Berry Amy L, Bou Zgheib Nadim, Chon Hye Sook, Shahzad Mian M, Judson Patricia L, Wenham Robert M, Apte Sachin M, Berglund Anders E, Magliocco Anthony M, Lancaster Johnathan M
Department of Women's Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Department of Women's Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA; Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Gynecol Oncol. 2016 Feb;140(2):259-63. doi: 10.1016/j.ygyno.2015.12.026. Epub 2015 Dec 28.
Ovarian cancer (OVCA) is the leading cause of mortality among women with gynecologic malignancy, in part due to the development of chemoresistance. We sought to identify micro-RNAs (miRNAs) associated with in vitro development of OVCA chemoresistance that may also represent potential targets for therapy.
In this study, four OVCA cell lines (A2780CP, A2780S, IGROV1, and OVCAR5) were serially treated with cisplatin in parallel with measurements of miRNA expression changes.
Nine miRNAs were found to be associated with increasing cisplatin resistance (IC50) (p<0.01); however, only 5 of these miRNAs have publically available information. Pathway analysis identified 15 molecular signaling pathways that were represented by genes predicted to be targets of the 5 miRNAs (false discovery rate<0.05), 11 of which are associated with the epithelial-mesenchymal transition (EMT). Further analysis identified 2 of those pathways as being associated with overall survival in 218 patients with OVCA.
Collectively, this panel of miRNAs associated with in vitro evolution of OVCA cisplatin resistance and the pathways identified to be associated with EMT and overall patient survival provide a framework for further investigations into EMT as a therapeutic target in patients with OVCA.
卵巢癌(OVCA)是妇科恶性肿瘤患者死亡的主要原因,部分原因是化疗耐药性的产生。我们试图鉴定与OVCA化疗耐药性体外发展相关的微小RNA(miRNA),这些miRNA也可能代表潜在的治疗靶点。
在本研究中,四种OVCA细胞系(A2780CP、A2780S、IGROV1和OVCAR5)与miRNA表达变化的测量同时,接受顺铂的连续处理。
发现9种miRNA与顺铂耐药性增加(IC50)相关(p<0.01);然而,这些miRNA中只有5种有公开可用信息。通路分析确定了15条分子信号通路,这些通路由预测为5种miRNA靶点的基因所代表(错误发现率<0.05),其中11条与上皮-间质转化(EMT)相关。进一步分析确定其中2条通路与218例OVCA患者的总生存相关。
总体而言,这组与OVCA顺铂耐药性体外演变相关的miRNA以及确定与EMT和患者总生存相关的通路,为进一步研究将EMT作为OVCA患者的治疗靶点提供了框架。